Gomersall J D, Stuart A
J Neurol Neurosurg Psychiatry. 1973 Aug;36(4):684-90. doi: 10.1136/jnnp.36.4.684.
A double-blind controlled clinical trial of crossover design was conducted in 26 volunteers suffering from migraine. Of 20 subjects who completed the trial, 16 had fewer attacks on amitriptyline than on placebo. Amitriptyline was found to have the greatest effect in reducing attacks with a short warning and in which no specific cause could be recognized. It had least effect in attacks with a long warning and recognized as due to fatigue. The drug was effective only in reducing those attacks with shorter duration and its effect was irrespective of severity. A dosage of between 10 and 60 mg, usually taken at night, was found to be adequate.
对26名偏头痛患者进行了交叉设计的双盲对照临床试验。在完成试验的20名受试者中,16名服用阿米替林时的发作次数比服用安慰剂时少。发现阿米替林在减少发作预警时间短且无法识别特定病因的发作方面效果最佳。在发作预警时间长且被认为是由疲劳引起的发作中效果最差。该药物仅在减少发作持续时间较短的发作方面有效,且其效果与严重程度无关。发现剂量在10至60毫克之间,通常在晚上服用就足够了。